Ormeloxifene in the management of abnormal uterine bleeding in tertiary care centre South Kerala
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20242072Keywords:
Ormeloxifene, Reproductive age group, Haemoglobin, Abnormal uterine bleedingAbstract
Background: AUB is the most common presentation in the reproductive age group. Many females suffer from AUB and its related effects. A study on the effectiveness of an easily available drug (ormeloxifene) with an easy dosing schedule was done and its wonderful role in controlling the symptoms and improvement of quality of life of a female with no financial burdens and surgical morbidity was studied.
Methods: A hospital based prospective observational study was conducted among women attending the outpatient clinic of OBG department at Dr Somervell Memorial CSI Medical College, Karakonam, Trivandrum district.
Results: Total 50 women with AUB took part in the study. 62% had menstrual duration of <7 days with regular cycles (84%). 86% of them had history of passage of clots. 48% of them had dysmenorrhea. Efficacy of ormeloxifene was assessed by using PBAC score and haemoglobin level measurement. A repeated measures ANOVA with a Greenhouse-Geisser correction determined mean PBAC score differed significantly between months. Post hoc analysis with a Bonferroni adjustment revealed PBAC score was statistically significantly decreased from pre-intervention to 3 months to 6 months. There is statistically significant difference with respect to haemoglobin level improvement.
Conclusions: Ormeloxifene is an excellent drug in controlling AUB as evidenced by the PBAC score and haemoglobin levels. Ormeloxifene has better compliance and acceptability. It is cost effective with a simple dosage schedule. A significant decrease in the menstrual blood loss and marked improvement in the hemoglobin concentration.
Metrics
References
Ravibabu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7(11):2534-6.
Kumari A, Prakash R. The role of ormeloxifene in the management of dysfunctional uterine bleeding: a prospective clinical study. Obstet Gynecol. 2018;5(1):6-11.
Biswas SC, Saha SK, Bag TS, Ghosh Roy SC, Roy AC, Kabiraj SP. Ormeloxifene, a selective estrogen receptor modulator, for treatment of dysfunctional menorrhagia. J Obstet Gynecol. 2004;54(1):56-9.
Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynaecol Res. 2009;35(4):746-52
Bhattacharyya TK, Banerji A. Efficacy of a selective estrogen receptor modulator: ‘ormeloxifene’ in management of dysfunctional uterine bleeding. South Asian Federat Obstet Gynaecol. 2010;2:207-11.
Shravage J, Mekhala D, Bellad MB, Ganachari MS, Dhumale HA. Ormeloxifene versus Medroxyprogesterone Acetate (MPA) in the treatment of Dysfunctional Uterine Bleeding: A double-blind randomized controlled trial. JSAFOG. 2011;3:21-4.
Agarwal N, Singh S, Agarwal M, Manocha P. Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2013;2(2):194-8.
Nandhini GM, Hiremath PB, Shameera BA. A study of efficacy of ormeloxifene in abnormal uterine bleeding of ovulatory disorders. Int J Reprod Contracept Obstet Gynecol 2022;11:1230- 5.
Bs D, Nanda SK. The role of sevista in the management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7(1):132-4.
Kriplani A, Kulshrestha V, Agarwal N. Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynaecol Res. 2009;35(4):746-52.
Fritz MA, Speroff L. Clinical Gynecologic Endocrinology and Infertility. 8th ed. South Asian edition: Lippincott Williams & Wilkins; 2005.
Downloads
Published
How to Cite
Issue
Section
